STTK · Shattuck Labs, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $1.00M | $0 | $0 | - | $3.00M | $1.61M | $1.11M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.95M | - | $7.62M | $8.68M | $9.92M | - | $16.31M | $19.24M | $16.26M | - |
| SG&A | $4.60M | - | $4.10M | $4.35M | $4.47M | - | $4.60M | $5.33M | $4.89M | - |
| Total Operating Expenses | $15.54M | - | $11.72M | $13.03M | $14.39M | - | $20.92M | $24.57M | $21.16M | - |
| D&A | $891.0K | - | - | - | $936.0K | - | - | - | $974.0K | - |
| Operating Income | ($15.54M) | - | ($10.72M) | ($13.03M) | ($14.39M) | - | ($17.92M) | ($22.96M) | ($20.04M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($14.77M) | - | ($10.06M) | ($12.46M) | ($13.70M) | - | ($16.68M) | ($21.55M) | ($18.50M) | - |
| EPS - Basic | ($0.13) | - | ($0.14) | ($0.24) | ($0.27) | - | ($0.33) | ($0.42) | ($0.37) | - |
| EPS - Diluted | ($0.13) | - | ($0.14) | ($0.24) | ($0.27) | - | ($0.33) | ($0.42) | ($0.37) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90.42M | $54.19M | $42.55M | $50.47M | $60.90M | $57.39M | $43.83M | $60.69M | $76.00M | $125.63M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.25M | $2.10M | $1.16M | $475.0K | $1.53M | $2.42M | $2.93M | $2.82M | $2.15M | $1.59M |
| Current Assets | $93.75M | $82.47M | $90.72M | $54.67M | $66.40M | $79.22M | $98.74M | $114.42M | $131.08M | $143.22M |
| Total Assets | $102.12M | $91.03M | $100.33M | $64.37M | $77.17M | $91.05M | $111.72M | $128.61M | $146.34M | $159.56M |
| Current Liabilities | $4.25M | $7.05M | $5.34M | $5.34M | $7.32M | $8.92M | $12.40M | $15.03M | $14.33M | $11.45M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.29M | $8.64M | $7.09M | $7.35M | $9.58M | $11.42M | $15.14M | $18.00M | $17.52M | $14.86M |
| Stockholders' Equity | $95.83M | $82.39M | $93.24M | $57.02M | $67.59M | $79.63M | $96.58M | $110.62M | $128.81M | $144.71M |
| Retained Earnings | ($445.30M) | ($430.53M) | ($417.94M) | ($407.88M) | ($395.42M) | ($381.72M) | ($363.04M) | ($346.37M) | ($324.81M) | ($306.31M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.42M) | - | - | - | ($12.03M) | - | - | - | ($16.16M) | - |
| Investing Cash Flow | $23.85M | - | - | - | $15.60M | - | - | - | ($33.28M) | - |
| Financing Cash Flow | $25.80M | - | - | - | ($57.0K) | - | - | - | ($184.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($16.16M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -1071.6% | - | - | - | -597.9% | -1427.1% | -1797.7% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -1710.3% | - |
| Net margin | - | - | -1005.6% | - | - | - | -556.4% | -1339.5% | -1659.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -1449.4% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.87 | - |
| R&D / Revenue | - | - | 761.8% | - | - | - | 544.3% | 1195.7% | 1458.7% | - |
| SG&A / Revenue | - | - | 409.8% | - | - | - | 153.6% | 331.4% | 439.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.5% | - | -10.0% | -19.4% | -17.8% | - | -14.9% | -16.8% | -12.6% | - |
| Return on equity | -15.4% | - | -10.8% | -21.8% | -20.3% | - | -17.3% | -19.5% | -14.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 22.06 | 11.70 | 17.00 | 10.25 | 9.08 | 8.88 | 7.96 | 7.62 | 9.15 | 12.51 |
| Quick ratio | 22.06 | 11.70 | 17.00 | 10.25 | 9.08 | 8.88 | 7.96 | 7.62 | 9.15 | 12.51 |
| Cash ratio | 21.28 | 7.68 | 7.97 | 9.46 | 8.33 | 6.44 | 3.53 | 4.04 | 5.30 | 10.97 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.07 | 1.10 | 1.08 | 1.13 | 1.14 | 1.14 | 1.16 | 1.16 | 1.14 | 1.10 |
| Liabilities / Assets | 0.06 | 0.09 | 0.07 | 0.11 | 0.12 | 0.13 | 0.14 | 0.14 | 0.12 | 0.09 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.01 | 0.00 | 0.00 | - | 0.03 | 0.01 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 7.5x | - | 1.9x | 0.7x | 0.7x | - | 1.8x | 1.8x | 3.5x | - |
| P / S | - | - | 172.5x | - | - | - | 59.2x | 121.8x | 405.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -66.6% | -100.0% | -100.0% | - | 336.9% | 704.5% | 1856.1% | - |
| Revenue CAGR (3y) | - | - | 67.7% | - | - | - | 16.4% | -20.3% | -27.9% | - |
| Revenue CAGR (5y) | - | - | -16.3% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -8.0% | - | 40.2% | 43.2% | 28.2% | - | 37.3% | -0.9% | 7.5% | - |
| Net income growth (YoY) | -7.8% | - | 39.7% | 42.2% | 26.0% | - | 39.5% | -1.0% | 10.7% | - |
| EPS growth (YoY) | 51.9% | - | 57.6% | 42.9% | 27.0% | - | 49.2% | 16.0% | 24.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 39.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 41.8% | 3.5% | -3.5% | -48.5% | -47.5% | -45.0% | -14.4% | -20.1% | -18.3% | -17.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.00M totalReportable Segment$1.00M · 100.0%
Product / service
$1.00M totalLicense$1.00M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Shattuck Labs against the 5 most active filers in the same SIC group.